|
 =access for Registered users.  =access for Subscribed users
One of the few successful investor–entrepreneurs with a good track record to come out of the UK, Dr. Andy Richards, will join Celtic Pharma Holding’s second Celtic Pharma fund’s advisory board. In 1992, he co-founded Chiroscience, one of Europe’s most successful biotech companies, and was its business development director through to the merger in 1999 with Celltech (now UCB). He is also founder of Arakis Ltd, which was acquired by Sosei in 2005, and Cambridge BioTechnology Ltd, acquired by Biovitrum in 2005. Click here.
European business angels cry out for help
EBAN, the European Business Angel Network, which represents 90 angel groups across Europe, is asking public policy makers for some help, including capacity building, help with filling the so called ‘equity gap’, cost of monitoring and collecting deal data, and subsidising the running of angel networks. So what should policy makers do to make sure that great innovations find access to finance at their early stages?
Braveheart weathers credit storm
Low interest and investment income from remaining cash funds, lower revenue from management operation, with selective investments to keep the portfolio companies alive, is resulting in dwindling cash balances.
3Q08 US VC Survey shows early signs of weakness
The number of quarterly VC deals and amounts continues to decline in the US Market, although the silicon valley cluster is weathering the pressure and had a small increase. Although the Fenwick & West Venture Capital Barometer™ showed an average price increase of 55 percent for companies receiving venture capital in 3Q08.
Kerry & Snowe rejuvenate the US SBIC program
As the UK government sponsored Enterprise Capital Fund (ECF) program (partly based on the US SBIC program) starts to get some traction with its first few investments, the goal post for the US SBIC program is already shifting. We look at the new bill passed by the US Senate that aims to rejuvenate the program, and consider what the UK ECF operators, planners and users can draw and learn from it.
Recent volatility will make VC returns look very healthy
Angels better than VCs?
Benchmark Capital creates Balderton Capital
China venture capital grew 55 percent in 2006
ETF closes $70m in first European cleantech fund
Pond Ventures: a VC fund with a live technology pulse
Update: Scotland’s Braveheart Angels Group cancels AIM floatation
Seraphim Capital, an angel-led fund with a mission
|
